HemoGenix Inc. Announces A Major Advancement To Promote Best Practices In Umbilical Cord Blood Testing And Patient Transplant Outcomes

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--HemoGenix® announced today that results from its HALO® family of cell therapy (CT) assays, which measure stem cell quality and potency of umbilical cord blood (UCB) units prior to transplantation, can now be uploaded to the National Marrow Donor Program (NMDP) EmTrax UCB database. The latter is used by stem cell transplantation centers to search for compatible cord blood units stored in public cord blood banks for patients requiring a stem cell transplant. The assays can promote “best practice criteria testing.” Inclusion of this stem cell data into the EmTrax database can provide the transplant physician with valuable, additional information regarding the ability and potential of the UCB stem cells to engraft prior to the transplantation procedure. This has been impossible using current “minimum testing criteria.”